Add-on saxagliptin improves glycemic status among uncontrolled type 2 diabetes mellitus
| Autor: | Madhusmita Sahu, Chakradhar Majhi, Butungeshwar Pradhan |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
endocrine system diseases business.industry Insulin medicine.medical_treatment nutritional and metabolic diseases Type 2 Diabetes Mellitus Incretin Saxagliptin medicine.disease Gastroenterology chemistry.chemical_compound Insulin resistance Postprandial chemistry Internal medicine medicine Glycated hemoglobin business Glycemic |
| Zdroj: | International Journal of Research in Medical Sciences. 6:1682 |
| ISSN: | 2320-6012 2320-6071 |
| DOI: | 10.18203/2320-6012.ijrms20181758 |
| Popis: | Background: Type 2 diabetes mellitus (T2DM) have multiple pathophysiologic defects contributing to hyperglycemia. T2DM patients have insulin resistance with progressive β-cell failure and progressive insulin secretion defect. Dipeptidyl peptidase-4 (DPP-4) inhibitors target the incretin system. saxagliptin is a DPP-4 inhibitor slowing the degradation of Glucagon-like peptide-1 (GLP-1) and Glucose-dependent insulinotropic peptide (GIP) sustain the incretin effects. Aim was to know the add-on effects of saxagliptin among uncontrolled T2DM.Methods: A total of 71 uncontrolled T2DM patients on various antidiabetic therapies except incretin mimetic were consecutively selected for the study. Baseline fasting plasma glucose (FPG), 2hour postprandial glucose (PPG) and glycated hemoglobin (HbA1c) was measured. Saxagliptin orally 5mg/day was given after approval of ethical committee and FPG, 2hour PPG and HbA1c was measured at 12 weeks and 24 weeks. Data were collected and analyzed by ‘t’ test using SPSS software version 25.Results: Baseline FPG, 2hour PPG and HbA1c was 158.4±13.9mg%, 252.6±24.4mg% and 8.6±1.3% respectively. Percentage of patients achieved HbA1c of |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|